Cargando…
Immunotherapy: an emerging modality to checkmate brain metastasis
The diagnosis of brain metastasis (BrM) has historically been a dooming diagnosis that is nothing less than a death sentence, with few treatment options for palliation or prolonging life. Among the few treatment options available, brain radiotherapy (RT) and surgical resection have been the backbone...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349473/ https://www.ncbi.nlm.nih.gov/pubmed/37454123 http://dx.doi.org/10.1186/s12943-023-01818-7 |
_version_ | 1785073914243710976 |
---|---|
author | Ahmad, Aatiya Khan, Parvez Rehman, Asad Ur Batra, Surinder Kumar Nasser, Mohd Wasim |
author_facet | Ahmad, Aatiya Khan, Parvez Rehman, Asad Ur Batra, Surinder Kumar Nasser, Mohd Wasim |
author_sort | Ahmad, Aatiya |
collection | PubMed |
description | The diagnosis of brain metastasis (BrM) has historically been a dooming diagnosis that is nothing less than a death sentence, with few treatment options for palliation or prolonging life. Among the few treatment options available, brain radiotherapy (RT) and surgical resection have been the backbone of therapy. Within the past couple of years, immunotherapy (IT), alone and in combination with traditional treatments, has emerged as a reckoning force to combat the spread of BrM and shrink tumor burden. This review compiles recent reports describing the potential role of IT in the treatment of BrM in various cancers. It also examines the impact of the tumor microenvironment of BrM on regulating the spread of cancer and the role IT can play in mitigating that spread. Lastly, this review also focuses on the future of IT and new clinical trials pushing the boundaries of IT in BrM. |
format | Online Article Text |
id | pubmed-10349473 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-103494732023-07-16 Immunotherapy: an emerging modality to checkmate brain metastasis Ahmad, Aatiya Khan, Parvez Rehman, Asad Ur Batra, Surinder Kumar Nasser, Mohd Wasim Mol Cancer Review The diagnosis of brain metastasis (BrM) has historically been a dooming diagnosis that is nothing less than a death sentence, with few treatment options for palliation or prolonging life. Among the few treatment options available, brain radiotherapy (RT) and surgical resection have been the backbone of therapy. Within the past couple of years, immunotherapy (IT), alone and in combination with traditional treatments, has emerged as a reckoning force to combat the spread of BrM and shrink tumor burden. This review compiles recent reports describing the potential role of IT in the treatment of BrM in various cancers. It also examines the impact of the tumor microenvironment of BrM on regulating the spread of cancer and the role IT can play in mitigating that spread. Lastly, this review also focuses on the future of IT and new clinical trials pushing the boundaries of IT in BrM. BioMed Central 2023-07-15 /pmc/articles/PMC10349473/ /pubmed/37454123 http://dx.doi.org/10.1186/s12943-023-01818-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Ahmad, Aatiya Khan, Parvez Rehman, Asad Ur Batra, Surinder Kumar Nasser, Mohd Wasim Immunotherapy: an emerging modality to checkmate brain metastasis |
title | Immunotherapy: an emerging modality to checkmate brain metastasis |
title_full | Immunotherapy: an emerging modality to checkmate brain metastasis |
title_fullStr | Immunotherapy: an emerging modality to checkmate brain metastasis |
title_full_unstemmed | Immunotherapy: an emerging modality to checkmate brain metastasis |
title_short | Immunotherapy: an emerging modality to checkmate brain metastasis |
title_sort | immunotherapy: an emerging modality to checkmate brain metastasis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349473/ https://www.ncbi.nlm.nih.gov/pubmed/37454123 http://dx.doi.org/10.1186/s12943-023-01818-7 |
work_keys_str_mv | AT ahmadaatiya immunotherapyanemergingmodalitytocheckmatebrainmetastasis AT khanparvez immunotherapyanemergingmodalitytocheckmatebrainmetastasis AT rehmanasadur immunotherapyanemergingmodalitytocheckmatebrainmetastasis AT batrasurinderkumar immunotherapyanemergingmodalitytocheckmatebrainmetastasis AT nassermohdwasim immunotherapyanemergingmodalitytocheckmatebrainmetastasis |